1. 1) Kaga A., Ishii T., Kanai S., Sasaki H., Ohsawa H., Shirai K., Jpn. J. Pharm. Health Care Sci., 30, 389–393 (2004).
2. 2) Ministry of Education, Culture, Sports, Science and Technology. “Yakugaku Kyoiku Model Core Curriculum.”: 〈https://www.mext.go.jp/a_menu/01_d/08091815.htm〉, cited 21 August, 2023.
3. 3) Misaki T., Nakazawa M., Tsutsumi K., Kayanuma T., Kamiyama Y., Fukasawa K., Tezuka H., Suzuki M., Hanawa T., Oguchi T., Yakugaku Zasshi, 129, 1265–1274 (2009).
4. 4) Hashimoto T., Ohkubo T., Takahashi N., Murai Y., Sato K., Terata S., Metoki H., Kikuya M., Hirasawa N., Tomioka Y., Oba M., Imai Y., Sato H., Jpn. J. Pharm. Health Care Sci., 38, 322–331 (2012).
5. 5) International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. “General Considerations for Clinical Studies E8(R1), Final version Adopted on 6 October 2021.”: 〈https://www.pmda.go.jp/files/000249610.pdf〉, cited 21 August, 2023.